Related content

Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity

By LLerena Adriáán   Dorado Pedro   Peññas-Lledóó Eva M  

Pharmacogenomics, Vol. 10, Iss. 1, 2009-01 ,pp. : 17-28

Future Medicine

Access to resources Recommend Favorite

Influence of CYP2C9 and CYP2D6 Polymorphisms on the Pharmacokinetics of Nateglinide in Genotyped Healthy Volunteers

By Kirchheiner J.  

Clinical Pharmacokinetics, Vol. 43, Iss. 4, 2004-01 ,pp. : 267-278

Adis International

Access to resources Recommend Favorite

Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo

By Wennerholm Agneta   Nordmark Anna   Pihlsgård Maria   Mahindi Margarita   Bertilsson Leif   Gustafsson Lars  

European Journal of Clinical Pharmacology, Vol. 62, Iss. 7, 2006-07 ,pp. : 539-546

Springer Publishing Company

Access to resources Recommend Favorite

Relevance of CYP2D6-1584C>G polymorphism for thioridazine:mesoridazine plasma concentration ratio in psychiatric patients

By Dorado Pedro   Peññas-LLedóó Eva M   de la Rubia Alfredo   LLerena Adriáán  

Pharmacogenomics, Vol. 10, Iss. 7, 2009-07 ,pp. : 1083-1089

Future Medicine

Access to resources Recommend Favorite

Relationship between CYP2D6 genotype and haloperidol pharmacokinetics and extrapyramidal symptoms in healthy volunteers

By Gassó Patricia   Papagianni Katerina   Mas Sergi   de Bobadilla Ramón Fernández   Arnaiz Joan Albert   Bernardo Miquel   Lafuente Amalia  

Pharmacogenomics, Vol. 14, Iss. 13, 2013-10 ,pp. : 1551-1563

Future Medicine

Access to resources Recommend Favorite